A 2-month-old girl with severe combined immunodeficiency (SCID), presented with mild staphylococcal skin infection, lymphopenia, low T cell number, absence of B cells, high number of NK cells, and a negligible response to mitogens. Since her older brother died as a result of SCID 2 years earlier, cord blood was harvested from a sister born 2. years earlier, who was normal and fully matched both by serology and molecular typing. In view of her clinical condition and in spite of a high number of NK cells with normal activity, HUCBT without preparative conditioning was performed. No G-CSF was administered. Engraftment with mixed chimerism was evident 3 weeks post transplantation. There were no peritransplantation complications. Eighteen months post transplantation, the girl is in excellent condition, blood counts are normal, T cell engraftment is complete, B cell engraftment is proceeding gradually, and the mitogen stimulation tests are normal. Due to the unique nature of HUCB hematopoietic cells, engraftment without conditioning may be possible in patients with SCID with fully matched donors. This is the first HUCBT performed without conditioning. Keywords: severe combined immunodeficiency (SCID); human umbilical cord blood transplantation (HUCBT); microsatellite sequences; mixed chimerism Severe combined immunodeficiency (SCID) is a heterogenous, lethal, congenital disorder of lymphoid progenitors resulting in the failure of T cells to respond to mitogens and specific antigens, and the inability of B cells to produce specific antibodies. SCID immunophenotypes can be classified according to the presence (B+ SCID) or absence (BϪ SCID) of B cells in the peripheral blood of the patients. There are several causes for the more common B+ SCID
Severe combined immunodeficiency (SCID) is a heterogenous, lethal, congenital disorder of lymphoid progenitors resulting in the failure of T cells to respond to mitogens and specific antigens, and the inability of B cells to produce specific antibodies. SCID immunophenotypes can be classified according to the presence (B+ SCID) or absence (BϪ SCID) of B cells in the peripheral blood of the patients. (70% of all SCID cases), including defects in the gamma chain common to the receptors for interleukin-2, 4, 7, 9, and 15 (X-linked SCID which accounts for 50-60% of SCID cases), defects in adenosine deaminase (ADA), or purine nucleoside phosphorylase (PNP), defects in the expression of the MHC, defective IL-2 production, impairment in the T cell receptor-CD3 complex, or T cell signal transduction pathways. 1 The most seriously affected SCID patients are those without detectable B cells (30% of all SCID patients). BϪ SCID is associated with in approximately half of the cases with inefficient V(D)J recombination events at the antigen receptor loci due to mutations in the recombinase activating genes (RAG). 1 In spite of the heterogeneity of genetic defects associated with SCID the phenotype is almost always fatal at an early age. ADA-deficient patients may be treated by gene or enzyme replacement therapy. However, for most patients, BMT is currently the only curative therapy for SCID. In 1968, the first successful BMT in an infant with X-linked SCID was performed. 2 Subsequently scores of these infants underwent successful BMT from related and unrelated donors. 3 Since the first successful transplantation of HUCB in a patient with Fanconi's anemia, 4 it has been used as a source of hematopoietic stem cells for transplantation to treat a variety of malignant and non-malignant hematologic disorders. 5 The unique nature of HUCB stem cells, (supported by some clinical observations although not proven) especially their high proliferative advantage, the relative immaturity of lymphocytes in cord blood which reduces the risk and severity of GVHD, the low rate of viral infections and many other advantages, encouraged many transplant teams to broaden the indications for HUCBT. We report the first HUCBT without conditioning in a child with SCID following 18 months of follow-up.
Case report
A 2-month-old girl, the daughter of Ashkenazi second degree related parents, presented with mild staphylococcal skin infection. Her brother was previously diagnosed as suffering from SCID at the age of 7 months. He later developed a variety of infectious complications and an oligoclonal pseudolymphoma which resolved with chemotherapy. However, at the age of 3 years, 2 years before the propositus' birth he succumbed to acute leukemia. The parents refused BMT.
The patient suffered from lymphopenia (10% of the white blood cell count), absolute lymphocyte count of 0.6 × 10 9 /l, CD3: 12%, CD4: 15%, CD8: 8%, CD2: 75%, CD 56: 32%, CD 20: 0% (Table 1) . NK activity as shown by cytotoxic activity against K562 and Daudi cells was normal. The Hb and platelet counts were normal. Normal activity for ADA and PN was noted. No mutations in the recombinase activating gene1 (RAG-1) or RAG-2 were found using the SSCP technique (Klauss Schwartz, the University of Ulm). There was a negligible response to mitogenic stimulation tests with phytohemagglutinin (PHA) and pokeweed mitogens (PWM). IgG, IgM and IgA levels were normal, however, there were no specific antibodies to viral antigens (adeno, herpes simplex, cytomegalo and varicella viruses), the Candida response was low, and the IgM response against herpes simplex virus (HSV) was negative. No maternal cells were found in the patient's peripheral blood as evidenced by microsatellite sequence studies.
Cord blood from another sibling was collected 2. years before the propositus's birth at the Israeli HUCB Bank at Hadassah University Hospital. A 99 ml sample of cord blood was collected in 20 ml of acid citrate dextrose, transferred to two freezing bags, mixed with an equal volume of cold 20% dimethylsulfoxide in minimal essential medium with no separation, and cooled in a controlled rate freezer before being frozen in liquid nitrogen. The donor was later found to be immunologically normal and HLA (both serologically and molecularly) compatible.
When the diagnosis of SCID was confirmed in this girl at the age of 3 months, the cord blood was transferred to our transplantation unit at the Sheba Medical Center where it was thawed. The removal of the hypertonic cryoprotectant was performed as described previously. 6 Briefly, immediately after being thawed, each PCB unit was diluted with an equal volume of solution containing 2.5% human albumin Kamapharm (Kibbutz Beit Kuma, Israel) in Reomacroden (Medisan) produced by Pharma & Upjohn, Norway in isotonic salt solution, with continuous mixing, and then centrifuged at 400 g for 10 min. The supernatant was removed and the sedimented cells were suspended slowly in fresh albumin/dextran solution to a volume of 50 ml for infusion to the patient. 5 × 10 8 cells/kg were transfused through a peripheral jugular vein. No conditioning was given. G-CSF as well as GVHD prophylaxis were not given. Engraftment, as evidenced by mixed chimerism (or split chimerism as no cell sorting was performed) in the microsatellite sequence studies, was achieved after 3 weeks (Figure 1) . Comparison of the microsatellite patterns post transplant with those obtained with mixtures of D and H DNA is compatible with little less than 20% donor cells. Stimulation tests became almost normal at 2 months post transplant (Table 2 ). There were no peritransplantation complications. Eighteen months post transplantation, the girl had normal blood counts, the microsatellite sequence studies showed constant mixed chimerism, the FACS profile was as follows: CD3: 46%, CD4: 39%, CD8: 7%, CD2: 67%, CD20: 8%, CD56: 22% (Table 1 ). The stimulation tests were normal (Table 2 ). One year post transplant the regular immunization program was initiated. After three rounds of vaccination the patient had detectable IgG antibodies against diphtheria toxoid (titer, 1:640), tetanus tox- (A was inherited from the same parent by the donor and host.) Post BMT all three alleles are present representing a mixed chimerism state due to the fact that no conditioning was given. The intensity of the donor allele B corresponds to lane 1, ie less than 20% donor cells. oid (titer, 1:640) and three strains of polio (titer Ͼ1:256).
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The child does not receive any drugs. Her psychomotor development and weight gain are normal.
Discussion
Over 500 HUCBT have been performed in the USA and Europe since 1988, 230 of which have been reported. 5,7-10 All patients receiving cord blood were conditioned with chemotherapy or radiochemotherapy. We hypothesized that the unique stem cells present in HUCB would be able to engraft in a non-conditioned marrow. As compared with hematopoietic stem cells from adults, hematopoietic stem cells in the cord blood have distinctive proliferative advantages, including the capacity to form more colonies in culture, a higher cycle rate, autocrine production of growth factors, longer telomeres, and a higher yield of transfection. [11] [12] [13] Indeed, gene therapy has been performed by transfecting HUCB in ADA-deficient SCID patients using fresh cord blood cells 14 and cryopreserved HUCB. 15 The fact that related cord blood reconstitutes the lymphoid functions in non-myeloablated SCID children is potentially very important for two reasons: first, related cord blood banking programs have been initiated all over the world but it is not clear yet what the cost-benefits ratio of these programs will be; second, up to now, lymphoid functions have been reconstituted best in non-ablated SCID patients when the children had been transplanted in utero. 16, 17 As opposed to in utero transplantation after the 16th week of gestation that is generally unsuccessful in human beings, SCID is an ideal disease for this treatment because graft rejection is unlikely.
Engraftment was achieved as evidenced by mixed chimerism shown in the microsatellite sequence studies 3 weeks post transplant. Sorted T and B cells in order to verify donor engraftment was not performed. However, as B cells were entirely absent from the host blood before BMT we assume that they are of donor origin. The problematic engraftment of B cells is typical of SCID transplants as only 50% of these patients are chimeric for donor B lymphocytes (however they often achieve reconstitution of B cell function). 18 In our patient there has been a gradual increase in the B cell percentage which was 0-1% for several months post transplant and is now 8%. The B cell function seems to be within the normal range as evidenced by the PWM stimulation test and by the normal specific antibodies response to immunization.
The question regarding the use of G-CSF to accelerate engraftment in HUCBT is still open. [8] [9] [10] Eurocord is conducting studies regarding this subject (A Nagler, personal communication). We preferred not to use growth factors again due to the fact that no conditioning was given and hence G-CSF, should it have been used, could give an advantage to host hematopoiesis. We hypothesize that the normal donor hematopoiesis will have biological advantages like the genetically corrected cells in ADA-deficient SCID. 19 Another important issue is that our patient had a high level of NK cells, with normal function known to delay engraftment or to cause rejections in mice in HLA-identical transplantations 20 and in humans in HLA-non identical T cell-depleted BMT for SCID. 21, 22 Many transplant teams are now giving cytoreductive therapy to these patients prior to transplantation. The relatively fast and smooth engraftment in this case again exemplifies the uniqueness of cord blood stem cells.
This case may be an example of the unique nature of HUCB stem cells, as they were able to engraft without conditioning and G-CSF in the marrow of a SCID patient with a high NK cell number. We have, however, to bear in mind that, at least in the mouse, high numbers of adult stem cells can overcome an unconditioned marrow environment. 23 It is of importance to note that although the donor cells represent less than 20% of the total cell population, immunological reconstitution according to markers and mitogenic stimulation tests was almost normal. Although no cell sorting was performed we assume that the lymphocytes, mainly the T cells, engrafted at a higher percentage, whereas the neutrophils are mainly of host origin.
Further studies will have to answer the question regarding the ability of unrelated HUCB to engraft and reconsti-tute the hemato-immunological system of SCID patients transplanted without conditioning.
